Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can't see the slides
Finally something to feel good about! Looking forward to the testing results, still hopeful..
Hopefully they aren't still reliant upon University students to perform the necessary work otherwise there are still another couple of weeks of winter break until they come back for the next semester.
Thanks DLucky, glad to know someone held them accountable for that.
With regard to the additional confirmatory tests, if they run them for 300 continuous hours that would be 12.5 straight days and they should already have those results as of 12/30 assuming they started on 12/18. Of course, I am assuming the testing is continuous and uninterrupted which may not be the case. I am also assuming they are similar to the description of the first run of preliminary tests.
Either way, investors at the very least deserve an updated product development timeline since Lightwave missed the last 2 items expected in 2014.
Same for my TD Ameritrade account
Sounds like the delay is in no way a negative, just need a little more time. Thanks for posting!
Care to elaborate?
I think it was intended as more of a joke/tongue-in-cheek post
Pessimist would say they are just up to their old tricks of using misdirection in an attempt to re-ignite investor enthusiasm, allowing them more time for whatever problems they still need to overcome.
Who knows really. But 300 hours of testing is twelve and a half continuous days worth. Wonder if they will have to test the coated modulators for the same amount of time... Pushing back my expectations for modulator testing results until February.
"demonstrated acceptable longevity and electro-optical activity to satisfy the demands of short-haul (metro) telecommunications and data communications networks."
"Acceptable" isn't exactly what you want to hear when the company describes their materials. Although if they were aware that their materials were't acceptable in the past then I guess this is a big step?
"We are currently running additional confirmatory tests at even higher temperatures before coating our best material systems on our proprietary designed, bleached waveguide modulator prototypes."
Sounds like it will be a bit longer yet until they put the material in the modulators and test. Kind of disappointed, thought that is what they had been doing since November.
My wife is a Senior Clinical Trial Manager and has said on multiple occasions that DF, Cedars Sinai, BI and many other well known research centers are notorious for moving very slowly, largely in part because their plates are always full and there is a lot of internal red tape that takes time to work through.
Aethlon's Study Details on Clinicaltrials.gov
Further study details as provided by Aethlon Medical Inc.:
Primary Outcome Measures:
Rate of adverse events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
Viral load reduction [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Viral load will be measured before and after each treatment with the investigational device.
Other Outcome Measures:
Quantification of viral copies captured. [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
The number of viral copies captured by the Aethlon Hemopurifier® during the first and last Hemopurifier treatments will be quantified.
Estimated Enrollment: 10
Study Start Date: December 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
OT:
Too funny, I am also in CTIX. Averaged in at $1.88 and looking forward to many near term milestones! It's been one hell of an end to 2014 so far, can't wait for what next year will bring there. Their pipeline is incredibly exciting :)
Was actually hoping for LWLG to meet their stated timeframes earlier this fall so I could take the profits and move them into CTIX as well. Part of why I was so negative/impatient back in November on this message board. Oh well, still curious to see what happens here, just not nearly as much as I used to be.
B-OM enrollment or dosing starts tomorrow???
Can't wait to see what happens when they follow up this week or next with a PR on the bottom line Ph2 Brilacidin results!!!
I agree with your DD and apologies if I came off harshly. To clarify, I'm not against taking the survey for the board, just sending it to Leo. Leo is kind enough to reply personally to many of our emails/concerns. He has already been generous enough to explain his reasoning to another user here and allow it to be posted in a public forum. I guess I just don't see any benefit in potentially sending him the message that the shareholders STILL don't trust him with this if that's what the results showed... Not that it has stopped him before (Polymedix asset acquisition/B trials ahead of Prurisol).
Now, if he's turning down a $200 per share buyout, then I am all for sending him the survey results
JMO
Please do not send this link and/or survey results to Leo. He is doing just fine and does not need to be ambushed by a bunch of uninformed armchair quarterbacks who don't have the inside info that Leo has as the CEO. There is no reason to question his decision regarding uplisting at this time.
Do you think you know better than Leo what this company should be doing at this time with all the near term news on the horizon (that we know about)???
No offense intended, and maybe it's just me, but your actions seem a little rash and counter-productive. I don't want him to worry about this kind of BS when planning the future of this company.
IMO one of those agreements may still be under development and on the table if it is right for CTIX. What was disclosed in the PR is just for one use of B and does not sound like it is exclusive to that one Large Pharma. Nothing has changed with regard to the potential for a B ABSSSI joint development agreement with upfront payments etc, IMO. It's nice to know that Big Pharma is/has been aware of CTIX and B and is watching closely.
My interpretation is that the FDA would have to at least approve Brilacidin for use in one anti-bacterial indication before they could complete the contract which makes sense. The large pharma wouldn't sign a deal for an unapproved anti-bacterial agent that they couldn't use in conjunction with their medical devices/implants. Timeframe to completion of the contract, IMO, would be correlated to the FDA approval of Brilacidin after a successful Phase 3 ABSSSI trial...2016 most likely.
I feel it is the quickest way to an up-list and institutional buyers. It would allow us to raise capital at reasonable share prices at fair terms with more reputable Finance companies.
I understand it is generally not in the average investor's best interest and would not suggest it if AEMD didn't need money to support future trials. Like I said before, if they time it right after positive results from their upcoming clinical trial, it could be a great benefit to the company.
Only large companies with high revenue should have share counts that large. AAPL certainly fits that criteria. I am not bashing, this would help the company if they time it right. After which, they could then start attracting institutional buyers.
Just because you write in bold does not make you right.
No it's not, the share count is too high IMO. This would be a good thing if they could time it with the release of positive results from the clinical trial they are starting soon.
I don't pay for the premium service so I can't private message you back.
Per the most recent 10-Q, there are 262,713,781 shares outstanding and 500,000,000 shares authorized.
I think those are fair questions.
What they really need now is a RS and an uplist to a major exchange within the next year. It would be great if they could time this with the release of positive results from the clinical trial they are starting soon (this month?) so it has minimal effect on the SP.
Per the most recent 10-Q, there are 262,713,781 shares outstanding and 500,000,000 shares authorized. They will never climb to the SP they need to be at in order to uplist without a RS.
I'm being completely real. My opinion shouldn't offend anyone. I'm not convinced at this point that their tech is worth very much because they haven't proven it out yet despite the hype that I bought into years ago. If and when they do, I very well might change my level of optimism.
Agreed Pit. This is really an all or nothing endeavor and ultimately just a waiting game. We may see the share price spike if they manage to announce a partnership or joint development agreement, or possibly with decent testing results, but really we are in sub-dollar land until they need cash again or something major happens. I think a year from now we will have a pretty good idea of whether anyone wants their technology.
I'd prefer a buyout, it's just too hard to say what advances could possibly make us obsolete within the next couple of years. With only several major players controlling what will be adopted as the next "standard", if we want to be selected as one of those adopted technologies we will really have to knock it out of the park with the material/devices they are producing.
After they finish testing the new devices in January, it will be another 2-3 month wait for their "partners" to test the devices themselves and potentially request changes (remember Lockheed?). It's hard to say how long/how many iterations of device/material changes it might take just to get a potential "partner" to want to use one of our products.
I would be thrilled with a $3 per share buyout.
How much time is left on the patent?
Based on the total from this Cubist chart on Daptomycin trials, can we assume that the number of patients in their Phase 3 trial amounted to ~235 for the Bacteremia chart or would that number be closer to their CSSSI chart with roughly 470 patients? Probably the "pivotal" CSSSI trial with 470 patients?
http://cubicin.com/datatour.html
Just trying to figure out how many patients we will need to enroll for our Phase 3.
How much time is left on their patent for the Hemopurifier???
TIA
No it does not, however we are less than 2 weeks away from being in December. Have to assume they will meet with the FDA in the first two weeks since things tend to slow down the closer to the holidays/new year that we get.
Nice to see that they plan to start the clinical trial by end of this month. It's about time....
It was slightly unclear but my understanding/interpretation is that even the patients at the lowest doses were included in the "50% of patients" comment. I'd guess that if you look at the later cohorts with higher doses that you'd see a much higher % of patients with enhanced p21 activation as they indicated in the statement below:
from the Q page 20 for Kevetrin:
" Presently, we believe we are at the latter stage of the trial as one patient in this cohort experienced a dose limiting toxicity (DLT). After experiencing the DLT, the patient requested to continue on the study and after review by physicians was allowed to, but given a lower dose of Kevetrin in the patient's weekly treatment. The trial protocol requires that we now complete six patients at the current dosing. The Company has received no notice of other events outside of the parameters of the protocol and the trial is progressing."
"In the recent cohorts, results showed significant enhancement of p21 expression in 50% patients and to a greater extent compared to earlier cohorts. This represents a positive signal for the development of Kevetrin."
Prurisol:
"We are meeting with the FDA in December 2014 to present our end of Phase 1 package and discuss our planned Phase 2/ 3 protocol. Upon FDA acceptance of our protocol, we will start the Phase 2/3 study."
Brilacidin-OM:
"On October 13, 2014 Cellceutix announced the acceptance of its IND (Investigational New Drug Application) by the Food and Drug Administration for the treatment of Oral Mucositis with Brilacidin. Presently sites are being set up, supplied, and trained. We expect our first patient to be enrolled in December 2014."
Brilacidin for Diabetic Foot Ulcer, Ophthalmic, and Otitic Infections:
"Further formulation work is needed for each indication. Upon a successful formulation the Company plans to advance these drugs into the clinic. The Company believes this work is challenging and will be completed in the first quarter of 2015."
Finances:
"As of September 30, 2014, a balance of $9.60 million remains and is available under the financing arrangement. From October 1, 2014 to October 27, 2014, the Company has generated additional proceeds of approximately $1,914,000 under the Common Stock Purchase Agreement with Aspire from the sale 800,000 shares of its common stock."
Agreed. Should get the 10-Q this week but that normally does not tell us much.
Not a buy unfortunately. Just compensation that we keep seeing each month:
"Explanation of Responses:
( 1) Acquired directly from the issuer in connection with Operations Committee work."